Joaquim Bellmunt, MD, PhD, Beth Israel Deaconess Medical Center, Boston, MA, presents an update of the DANUBE study (NCT02516241), evaluating PD-L1 as a predictive marker of immunotherapy benefit in patients with previously untreated metastatic urothelial carcinoma (mUC). The TC/IC25 algorithm is predictive of longer survival in patients treated with durvalumab or durvalumab plus tremelimumab but it is not prognostic; however, PD-L1 expression can play a role in identifying patients with mUC that benefit from immunotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

свернуть